SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia—a phase II randomised control trial study protocol

BACKGROUND: Sodium valproate (VPA) has been associated with a reduced risk of head and neck cancer development. The potential protective mechanism of action is believed to be via inhibition of histone deacetylase and subsequent epigenetic reprogramming. SAVER is a phase IIb open-label, randomised co...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Trials
Asıl Yazarlar: McCarthy, Caroline, Sacco, Joseph, Fedele, Stefano, Ho, Michael, Porter, Stephen, Liloglou, Triantafillos, Greenhalf, Bill, Robinson, Max, Young, Bridget, Cicconi, Silvia, Chauhan, Seema, Tesfaye, Binyam, Jackson, Richard, Sherratt, Frances, Shaw, Richard
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2021
Konular:
Study Protocol
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8256209/
https://ncbi.nlm.nih.gov/pubmed/34225765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-021-05373-8
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller